The control exerted by the INK4a/ARF locus on cellular proliferation is crucial to restrict tumor development. In agreement with this, mice with defects in this locus are highly tumor prone. However, the potential contribution of other pathways in modulating tumorigenesis in the absence of INK4a/ARF is largely unexplored. In the present study, we investigated the consequences of the combined loss of either of two cyclin-dependent kinase inhibitors, p21 and p27, in cooperation with deletion of the INK4a/ARF locus. Our results show a clear differential effect in tumorigenesis depending on the CKI that is absent. The absence of p21 produced no overt alteration of the lifespan of the INK4a/ARF-null mice, although it modified their tumor spectrum, causing a significant increase in the incidence of fibrosarcomas and the appearance of a small number of rhabdomyosarcomas. In contrast, deficiency of p27 resulted in a significant increase in lethality due to accelerated tumor development, especially in the case of T-cell lymphomas. Finally, combined deficiency of INK4a/ARF and p27 resulted in a significant increase in the number of metastatic tumors. These results demonstrate genetically the oncogenic cooperation between defects on INK4a/ ARF and p27, which are common alterations in human cancer.
Introduction
The eukaryotic cell cycle is driven by the concerted action of kinase complexes composed of an activator subunit, the cyclin, and a catalytic subunit, the cyclindependent kinase (CDK). The critical transition from the G1 phase of the cell cycle to the S phase requires the activities of two groups of such kinase complexes, the Dtype cyclin-CDK4/6 and the E/A-type cyclin-CDK2 (Wuarin and Nurse, 1996; Morgan, 1997) . The activity of these enzymes is restricted by the inhibitory action of two families of CDK inhibitors (CKIs), the INK4 family and the Cip/Kip family (Sherr and Roberts, 1999) . Members of the Cip/Kip family, p21 Waf1/Cip1 , p27 Kip1 and p57 Kip2 , specifically bind to and block the activity of CDK2 complexes, while members of the INK4 family, p16 INK4a , p15 INK4b , p18 INK4c and p19 INK4d , target CDK4/6, thereby preventing their binding to the stimulatory subunit, the D cyclin. In addition, Cip/Kip members can associate with CDK4/6 complexes and have a stimulatory effect by promoting the assembly of the active cyclin-CDK complex (Sherr and Roberts, 1999) .
The above network of kinases and their positive and negative regulators have a common goal, to integrate the information needed by the cell to decide whether to enter into a new round of cell division or to stay quiescent. This information is integrated on the retinoblastoma protein (pRb), making this gene a critical regulator of cell cycle progression and placing it as a central target for the actions of tumorigenic events (Sherr and McCormick, 2002) . This is highlighted by the fact that abnormal regulation of the Rb pathway is among the most common alterations in human cancer, together with the loss of p53 activity. Control of these two crucial pathways is exerted in part by the INK4a/ARF locus, which encodes two different proteins with different activities. INK4a produces p16, a Dtype cyclin kinase inhibitor, while ARF promotes p53 stability and function (Lowe and Sherr, 2003) . The importance of this locus is underscored by the fact that its inactivation is the second most frequent alteration in human cancer after inactivation of p53 (Ruas and Peters, 1998) . Mouse models with genetically engineered defects in this locus have proven highly tumor prone, further supporting the involvement of these gene products in restricting tumorigenesis in vivo (Serrano, 2000) .
The generation of mouse models to study the tumor suppressor potential of p21 and p27 have revealed that p21-null mice develop tumors at an advanced age (Deng et al., 1995; Martin-Caballero et al., 2001) , and that p27null mice develop benign pituitary adenomas with very long latency periods (Fero et al., 1996; Kiyokawa et al., 1996; Nakayama et al., 1996) . The role of these proteins in facilitating tumor formation and development has also been demonstrated in combination with other genetic alterations. Thus, the absence of p21 accelerates the development of some tumors, such us pituitary tumors in Rb-haploinsufficient mice and in INK4c-null mice (Brugarolas et al., 1998; Franklin et al., 2000) , breast tumors in Ras transgenic mice (Adnane et al., 2000; Bearss et al., 2002) and intestinal tumors in Apc-haploinsufficient mice (Yang et al., 2001) . In contrast, the absence of p21 has no effect on the tumor-prone phenotype of mice deficient for the Werner syndrome gene (Lebel et al., 2001) , nor in Myc-induced lymphomas (Martins and Berns, 2002) and mammary tumors (Bearss et al., 2002) . More surprisingly, p21 deficiency even delays the onset of thymic lymphomas in ATM-null mice (Wang et al., 1997) and presented reduced susceptibility to radiationinduced tumors (Martin-Caballero et al., 2001) . Finally, there are contradictory results concerning the susceptibility of p21-null mice to chemically induced carcinogenesis of the skin (Topley et al., 1999; Weinberg et al., 1999) .
A number of mouse models carrying specific oncogenic lesions also support a role for p27 in tumorigenesis. Pten heterozygosity leads to the development of prostatic intraepithelial neoplasia (PIN) in 50% of the mice. When Pten þ /À mice are crossed into a p27-null background, all the animals develop PIN and some of them progress to carcinoma, with even some cases of invasive tumors observed (Di Cristofano et al., 2001) . Conceptually similar, other examples of the oncogenic effects of p27 deficiency are: the increased incidence of pituitary tumors when p27 deficiency is combined with Rb þ /À mice (Park et al., 1999) or with CDK4-R24C transgenic mice (Sotillo et al., 2001) ; the development of genital tumors, when p27 deficiency is combined with deficiency in inhibin (Cipriano et al., 2001) ; the increased appearance of colon tumors, in combination with Apc þ /À (Philipp-Staheli et al., 2002) ; and the increased incidence of lymphomas, in combination with transgenic Em-myc (Martins and Berns, 2002) or cyclin E (Geisen et al., 2003) .
In the present study, we have addressed the analysis of the combined deficiency of either one of these two CKIs of the Cip/Kip family, p21 and p27, on an INK4a/ARFnull background.
Results

Analysis of mice lacking p21 on an INK4a/ARF-null background
We initiated our study by following a colony of INK4a/ ARF-deficient mice (n ¼ 56) of a mixed genetic background (60% C57BL/6; 37.5% 129Sv; 2.5% SJL) over their entire lifespan. This analysis allowed us to assign a maximum lifespan of 10 months and a tumor penetrance of 94% with an average tumor latency of 6 months ( Figure 1 and Table 1 ). Detailed histopathological analysis revealed that the main tumor pathologies developed by these animals were histiocytic sarcomas (57.6%), lymphomas (12.2%) and fibrosarcomas (10.6%), as reported previously (Serrano et al., 1996) (see Figure 2 ).
To examine the tumorigenic cooperativity between the absence of both p21 and INK4a/ARF, mice were crossed to generate a colony of INK4a/ARF/p21-null animals (n ¼ 52) of mixed genetic background (55% C57BL/6; 43.7% 129Sv; 1.3% SJL) that were followed until death ( Figure 1 and Table 1 ). All the animals died before 10 months of age, and the incidence of tumors was 94% with a mean latency of 6 months. Histopathological analysis revealed that the tumor spectrum of Figure 1 Decreased survival of INK4a/ARF-null mice with combined deficiency of p21 or p27. Survival curves of tumorbearing mice for the different genotypes. Only the lack of p27, and not p21, accelerated tumor appearance of INK4a/ARF-null mice. Tumor penetrance was close to 100% in all colonies (see Table 1 ) and, for this reason, the survival curves of tumor-bearing mice are essentially identical to those of all mice (not shown). The only exception are the p21-null mice in which there is a high incidence of death due to renal failure, as reported previously (Balomenos et al., 2000; Martin-Caballero et al., 2001) The primary tumors and the location of metastases was as follows: for INK4a/ARF-null mice, five histiocytic sarcomas and one osteosarcoma to lung; for INK4a/ARF/p21-null mice, eight histiocytic sarcomas to lung, and one fibrosarcoma to kidney; and for INK4a/ARF/p27-null mice, 10 histiocytic sarcomas to lung, and one lymphoma, one hemangioma and one gastric carcinoma to brain. b All the values of incidence are relative to the total number of mice, that is, for INK4a/ARF-null mice (n ¼ 56), for INK4a/ARF/p21-null mice (n ¼ 52) and for INK4a/ARF/p27-null mice (n ¼ 52) Figure 2) , with the exception of a significantly increased incidence of fibrosarcomas (from 10.6 to 30.6%) (Fisher's exact test, Po0.003). Although at very low frequency, the appearance of rhabdomyosarcomas was also notable (see Figure 3 , panels a and b for an example), a tumor type not present in either INK4a/ARF-null or p21-null mice. The increased incidence of fibrosarcomas and rhabdomyosarcomas demonstrates a synergistic effect of the lack of these genes in the development of these specific pathologies. Further supporting this idea is the fact that both, fibrosarcomas and rhabdomyosarcomas, showed not only increased incidence but also a higher degree of malignancy, extending through whole limbs and quickly invading adjacent tissues. Of note, the INK4a/ARF locus has been previously involved in the development of rhabdomyosarcomas when INK4a/ARF deficiency is combined with aberrant c-Met signaling (Sharp et al., 2002) . In contrast to the increased incidence of fibrosarcomas and rhabdomyosarcomas, the lack of lung adenomas/carcinomas in the triple knockout animals was striking, given the fact that they represent 7.5% of all the tumors present in INK4a/ARF animals. Furthermore, single p21-null mice also developed this kind of tumors with an incidence of 4.6% (Martin-Caballero et al., 2001) , although with a much longer latency period of 19 months (our unpublished observations). In this sense, we also noticed the absence in INK4a/ARF/ p21-null mice of other tumor types present at low incidence in the INK4a/ARF-null mice, such as osteosarcomas, pituitary and brain tumors (3, 1.5 and 1.5% incidence, respectively, in INK4a/ARF-null mice). Together, these results argue for a negative effect of p21 deletion in the development of particular types of spontaneous tumors. This intriguing observation is in agreement with similar results pointing to an antitumoral effect of p21 deficiency on radiationinduced (Martin-Caballero et al., 2001) and ATMinduced (Wang et al., 1997) lymphomagenesis. Together, these observations place p21 in a previously unsuspected role facilitating tumor progression in certain settings.
Finally, another important consequence of the combined absence of p21 and INK4a/ARF was a slight increase in the number of metastases observed (14.5% compared to 10.6% for INK4a/ARF-null mice; Table 1 ). This result is in accordance with a recent report in which an increased incidence of metastasis in p21 nullizygous mice after irradiation was described, concluding that p21 functions as an antimetastatic agent (Jackson et al., 2003) .
Thus, our results show a synergistic effect of loss of p21 and INK4a/ARF in the development and progression of certain tumors with a concurrent impaired tumor progression in particular tissues. 
Analysis of mice lacking p27 on an INK4a/ARF-null background
To study the interaction between the INK4a/ARF locus and the CKI p27, we analysed a colony of triple knockout mice (n ¼ 52) of mixed genetic background (55% C57BL/6; 43.7% 129Sv; 1.3% SJL). Combined deficiency of p27 and INK4a/ARF caused a significant shortening of the lifespan (log-rank test, Po0.0001) (see Figure 1 ). Tumor penetrance was 97% and the mean latency was 4.5 months (Table 1 ). Histopathological analysis showed that, interestingly, the most frequent tumors were lymphomas (42%). This high incidence of lymphomas represents a significant increase with respect to the INK4a/ARF-null mice that showed a 12.2% incidence for this neoplastic lesion (Fisher's exact test, Po0.0001) ( Figure 2 ). Other tumor types presented a slightly reduced incidence (histiocytic sarcomas, 34.4%; fibrosarcomas, 6.2%; lung adenomas/ carcinomas, 4.6%), probably as a consequence of the increased appearance and early onset of lymphomas ( Figure 2) . Moreover, in all cases tumors developed earlier in the absence of p27. Together, these observations suggest a strong synergistic effect of the combined deficiency of INK4a/ARF and p27 in the genesis of tumors.
In contrast to what is observed for INK4a/ARF-null animals where 100% of the lymphomas are of B-cell origin, immunostaining against the surface marker CD3 revealed that a high proportion (40%) of the lymphomas developed by INK4a/ARF/p27 compound mutant mice were of T-cell origin (see Figure 3 , panels c and d for an example). This effect of p27 on the phenotype of the lymphoid tumor cells is more pronounced than that observed for the INK4a/ARF/p21-null mice, with only 15% of the lymphomas positive for CD3. This suggests that the lack of p27 on an INK4a/ARF-null background favors the unrestricted proliferation of T-lymphoid cells. These lymphomas were invasive, extending and infiltrating different organs, mainly the spleen, liver, lymph nodes and thymus. The high incidence of lymphomas and their invasive phenotype is not the result of the addition of the individual contribution of INK4a/ARF and p27 deficiencies, since p27-null mice do not present this type of neoplasia and the INK4a/ARF-null mice present only a modest incidence of lymphomas with low invasivity. Consequently, the data presented here show a strong synergism between loss of p27 and INK4a/ARF in the development and malignancy of T-cell lymphomas.
Of special interest was the observation of an increased incidence of metastasis in INK4a/ARF/p27-null mice (20.3%) with respect to INK4a/ARF animals (10.6%) (Fisher's exact test, P ¼ 0.06) (Table 1 ). In addition, metastases appeared earlier in INK4a/ARF/p27-null mice (4.6 months compared to 7 months in the INK4a/ ARF-null mice), further suggesting a role for p27 in restricting metastasis development. In most cases, these metastases were originated by histiocytic sarcomas and were located in the lung, although we also found some metastases in the brain from tumors of different origin (see Figure 3 , panels e and f for an example of a gastric carcinoma that metastasized to brain).
In summary, the absence of p27 on an INK4a/ARFnull background results in increased lethality with an augmented appearance of lymphomas and a high incidence of metastasis. These results clearly show a cooperative contribution to tumor suppression of p27 and INK4a/ARF.
Discussion
The purpose of our study was to evaluate the potential cooperation in neoplastic transformation of loss of two different members of the Cip/Kip family of CKIs in the highly tumor-prone INK4a/ARF mouse. We have performed a detailed analysis of survival and tumor susceptibility on colonies of deficient animals over an extended period of time. As a result, we have observed that deficiency of p21 or p27 had a different impact on the appearance of tumors and overall survival of the INK4a/ARF-null mice. The absence of p27 in combination with mutant INK4a/ARF resulted in a significant acceleration of tumor development and progression that culminated in decreased survival. In contrast, p21 deficiency in the context of INK4a/ARF-null mice had a modest effect on tumorigenesis and survival.
Tumor spectrum in the absence of p21 was unaltered except for an increase in the number of fibrosarcomas and the appearance of a small number of rhabdomyosarcomas, a tumor type not present in either p21-or INK4a/ARF-null mice. This result is in agreement with a previously characterized role of p21 in mediating myogenic differentiation (Parker et al., 1995) and in the development of rhabdomyosarcomas (Sharp et al., 2002) . Other tumor types were surprisingly absent after p21 deficiency. Previously, we and others have described a similar antitumorigenic effect of p21 deficiency on radiation-induced lymphoma (Martin-Caballero et al., 2001) and on lymphomas spontaneously produced in ATM-deficient mice (Wang et al., 1997) . The antitumorigenic effect of p21 deficiency could be conceivably related to an indirect exacerbation of p53-dependent apoptotic pathways in the absence of p21. Altogether, available evidence indicates that p21 deficiency confers a growth advantage to neoplastic development in certain tissues, while it has the opposite effect in others.
In contrast to p21, our results show that deletion of p27 on an INK4a/ARF-null background significantly accelerates tumorigenesis. Not only tumors appeared earlier but also were more aggressive and with a higher degree of malignancy. In this sense, a significant increase in the development of lymphomas was observed (from 12.2 to 42%) with a high proportion of them (40%) of T-cell origin. Mice lacking p27 show minor alterations in the thymus and do not develop lymphomas, even at an advanced age (Fero et al., 1996; Kiyokawa et al., 1996; Nakayama et al., 1996) . However, combination of p27 deficiency with a number of additional genetic lesions has demonstrated a significant role of p27 in Tcell lymphomagenesis. In particular, cyclin E transgenic p21 and p27 cooperation with INK4a/ARF J Martín-Caballero et al mice developed T-cell lymphomas only when combined with p27 deficiency (Geisen et al., 2003) . Similarly, the absence of p27 accelerates the appearance of T-cell lymphomas in p53-null mice (Philipp-Staheli et al., 2003) and in retrovirally induced and Myc-induced lymphoma mouse models (Martins and Berns, 2002) . Finally, p27 protein levels are frequently low in human lymphomas and this reduced expression is associated with poor prognosis (Sanchez-Beato et al., 1997; Erlanson et al., 1998; Quintanilla-Martinez et al., 1998; Chiarle et al., 2000; Moller, 2000) . Taken together, our results and previous work by others provide genetic evidence for the involvement of p27 in T-cell lymphoma development.
Another remarkable finding is that the lack of p27 resulted in a considerable increased incidence of metastasis that, together with the faster development of tumors in the absence of p27, makes the contribution of p27 to malignancy even more compelling. As already mentioned in the introduction, while other authors have reported a similar effect of p27 deficiency in accelerating neoplastic transformation, the putative impact of p27 on the metastatic potential of tumors has remained largely unexplored. The present analysis of INK4a/ARF/p27null mice constitutes the first demonstration of the impact of p27 on the metastatic potential of tumors.
A possible mechanism to explain p27 contribution to the observed increase in tumor development and malignancy of the INK4a/ARF-null mouse could be related to the antiproliferative action of p27 acting as a CKI. Concomitant deletion of p16 and p27 may have an additive effect on the phosphorylation and ensuing inactivation of pRb. This would lead to an acceleration in tumor development and to a metastatic phenotype similar to the one observed in Rb-haploinsufficient mice (Nikitin et al., 1999) . Another potential explanation could be provided by loss of what has been suggested by other authors as a proapoptotic action of p27 (Carneiro et al., 2003) .
Mutations in p21 and p27 genes are rare events in human cancer. Nevertheless, their expression or activity is frequently diminished in tumors. Reduced levels of p21 have been observed frequently in colorectal cancers and are indicative of low survival rates (Zirbes et al., 2000) . Another factor influencing p21 activity is mutation of p53, a well-known transcriptional activator of p21 and the most common alteration in human cancer. Diminished levels of p27 have been reported in human cancers and these alterations correlate with poor prognosis (Lloyd et al., 1999; Tsihlias et al., 1999; Slingerland and Pagano, 2000; Philipp-Staheli et al., 2001) . Another mechanism of inactivation of p27 is mislocalization to the cytoplasm (Ciaparrone et al., 1998; Baldassarre et al., 1999; Hurteau et al., 2001) , an event that directly correlates with poor survival and tumor grade in Barrett's esophagus and breast carcinoma (Singh et al., 1998; Liang et al., 2002; Shin et al., 2002; Viglietto et al., 2002) . Furthermore, a number of reports have described that concurrent loss of p16 and p27, alone or in combination with p53 mutation, correlates with progression and aggressiveness in differ-ent human cancers (Myung et al., 2000; Sanchez-Beato et al., 2001; Zhang et al., 2002) . Our report provides genetic demonstration of the strong tumorigenic cooperation between loss of INK4a/ARF and p27.
Materials and methods
Mice and animal handling
The parental strains of mice used in this work are wild type (50% C57BL/6; 50% 129Sv), p21 null (50% C57BL/6; 50% 129S2/SvPas) (Brugarolas et al., 1995) , p27 null (50% C57BL/ 6; 50% 129S4/SvJaeSor) (Fero et al., 1996) and INK4a/ARFnull (60% C57BL/6; 37.5% STOCK 129/Sv; 2.5% SJL) (Serrano et al., 1996) . Animals were housed at the National Center of Biotechnology (Madrid, Spain) in a pathogen-free barrier area. Moribund mice were killed humanely in accordance with the Guidelines for Humane End Points for Animals used in Biomedical Research. Tumor latency has been considered equivalent to lifespan.
Histological analysis
Tumors from nonautolysed tissues were recovered from moribund or recently deceased mice. Tissue samples were fixed in 10% buffered formalin, embedded in paraffin wax, sectioned at 4 mm and stained with hematoxylin and eosin (H&E). Immunohistochemical staining was performed using the streptavidin-biotin-peroxidase complex method. Tissue sections were processed with 10 mM citrate buffer (pH 6.0) in a microwave (1001C, 15 min). Endogenous peroxidase activity was inactivated by incubation with 3% hydrogen peroxide in methanol (15 min, room temperature). Tissue sections were incubated in a humidity chamber (overnight, 41C) using the following markers: for B-lymphocyte detection, rat anti-mouse CD45R/B220 monoclonal antibody (mAb) (Southern Biotechnology Associates, Birmingham, AL, USA; dilution 1 : 100); for T-lymphocyte detection, rabbit anti-human CD3 polyclonal antibody (Dako, Glostrup, Denmark; 1 : 100); for the diagnosis of histiocytic sarcomas, rat anti-mouse F4/80 (BMA Biomedicals AG, August, Switzerland; dilution 1 : 20); for the diagnosis of rhabdomyosarcomas, mouse anti-human desmin (Sigma Chemicals Co; dilution 1 : 100); for diagnosis of fibrosarcoma, goat anti-human vimentin (Dako dilution 1 : 20). The antibodies were diluted in Tris-buffered saline (TBS). Primary antibodies were omitted for negative controls. After three rinses in TBS, 5 min each, samples were incubated with a secondary antibody. For the detection of the corresponding primary antibodies, we used biotinylated goat anti-rabbit IgG (Vector Laboratories, Burlingame, CA, USA; 1 : 400); biotinylated rabbit anti-rat IgG (Vector), biotinylated rabbit anti-mouse IgG (Vector) and biotinylated rabbit antigoat IgG (Vector). After 30 min incubation with the secondary antibody, tissue sections were incubated with streptavidin conjugated with peroxidase, diluted 1 : 20 in TBS (Zymed Laboratories, Inc.) for 30 min at room temperature. The chromogen was 3-3 0 -diaminobenzidine tetrahydrochloride (Sigma), diluted 0.002% in TBS, in the presence of 0.01% hydrogen peroxide. The nuclei were counterstained with Harris hematoxylin for 1 min. Images were captured with a DP-10 digital camera in an Olympus Vanox microscope. ogy. Work at the laboratory of MS has been funded by the Spanish Ministry of Science and Technology (SAF2002-03402) and by the European Union (QLRT-2000-02084, QLRT-2000-00616 and INTACT).
